Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Two Different Doses of Palonosetron Compared to Ondansetron in the Prevention of CINV in Pediatric Patients Undergoing Single and Repeated Cycles of MEC or HEC
Status: Enrolling
Updated:  10/25/2012
Upstate Medical University
mi
from
Syracuse, NY
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Two Different Doses of Palonosetron Compared to Ondansetron in the Prevention of CINV in Pediatric Patients Undergoing Single and Repeated Cycles of MEC or HEC
Status: Enrolling
Updated: 10/25/2012
Upstate Medical University
mi
from
Syracuse, NY
Click here to add this to my saved trials
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Two Different Doses of Palonosetron Compared to Ondansetron in the Prevention of CINV in Pediatric Patients Undergoing Single and Repeated Cycles of MEC or HEC
Status: Enrolling
Updated:  10/25/2012
Department of Pediatrics
mi
from
Valhalla, NY
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Two Different Doses of Palonosetron Compared to Ondansetron in the Prevention of CINV in Pediatric Patients Undergoing Single and Repeated Cycles of MEC or HEC
Status: Enrolling
Updated: 10/25/2012
Department of Pediatrics
mi
from
Valhalla, NY
Click here to add this to my saved trials
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Two Different Doses of Palonosetron Compared to Ondansetron in the Prevention of CINV in Pediatric Patients Undergoing Single and Repeated Cycles of MEC or HEC
Status: Enrolling
Updated:  10/25/2012
Nationwide Children's Hospital
mi
from
Columbus, OH
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Two Different Doses of Palonosetron Compared to Ondansetron in the Prevention of CINV in Pediatric Patients Undergoing Single and Repeated Cycles of MEC or HEC
Status: Enrolling
Updated: 10/25/2012
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Two Different Doses of Palonosetron Compared to Ondansetron in the Prevention of CINV in Pediatric Patients Undergoing Single and Repeated Cycles of MEC or HEC
Status: Enrolling
Updated:  10/25/2012
Medical University of South Carolina
mi
from
Charleston, SC
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Two Different Doses of Palonosetron Compared to Ondansetron in the Prevention of CINV in Pediatric Patients Undergoing Single and Repeated Cycles of MEC or HEC
Status: Enrolling
Updated: 10/25/2012
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Two Different Doses of Palonosetron Compared to Ondansetron in the Prevention of CINV in Pediatric Patients Undergoing Single and Repeated Cycles of MEC or HEC
Status: Enrolling
Updated:  10/25/2012
Cook Children's Medical Center
mi
from
Ft. Worth, TX
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Two Different Doses of Palonosetron Compared to Ondansetron in the Prevention of CINV in Pediatric Patients Undergoing Single and Repeated Cycles of MEC or HEC
Status: Enrolling
Updated: 10/25/2012
Cook Children's Medical Center
mi
from
Ft. Worth, TX
Click here to add this to my saved trials
Ketogenic Diet in Advanced Cancer
A Low-Carbohydrate Diet for Advanced or Metastatic Cancer
Status: Enrolling
Updated:  10/26/2012
VA Pittsburgh Healthcare System
mi
from
Pittsburgh, PA
Ketogenic Diet in Advanced Cancer
A Low-Carbohydrate Diet for Advanced or Metastatic Cancer
Status: Enrolling
Updated: 10/26/2012
VA Pittsburgh Healthcare System
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Relaxation and Visualization Therapy for Breast Cancer Patients
A Feasibility Study of Relaxation and Visualization Therapy for Breast Cancer Patients
Status: Enrolling
Updated:  10/29/2012
Oregon Health and Science University
mi
from
Portland, OR
Relaxation and Visualization Therapy for Breast Cancer Patients
A Feasibility Study of Relaxation and Visualization Therapy for Breast Cancer Patients
Status: Enrolling
Updated: 10/29/2012
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Prospective Analysis of Changes in Background Parenchymal Enhancement (BPE) and Amount of Fibroglandular Tissue on Breast MRI
Prospective Analysis of Changes in Background Parenchymal Enhancement (BPE) and Amount of Fibroglandular Tissue on Breast MRI in Early Stage Breast Cancer Patients on Tamoxifen
Status: Enrolling
Updated:  10/29/2012
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Prospective Analysis of Changes in Background Parenchymal Enhancement (BPE) and Amount of Fibroglandular Tissue on Breast MRI
Prospective Analysis of Changes in Background Parenchymal Enhancement (BPE) and Amount of Fibroglandular Tissue on Breast MRI in Early Stage Breast Cancer Patients on Tamoxifen
Status: Enrolling
Updated: 10/29/2012
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Stage IIIB/IV Non-Small Cell Lung Cancer
Pazopanib and Weekly Paclitaxel in Stage IIIB/IV Non-small Cell Lung Cancer
Status: Enrolling
Updated:  10/29/2012
Loyola University Medical Center
mi
from
Maywood, IL
Stage IIIB/IV Non-Small Cell Lung Cancer
Pazopanib and Weekly Paclitaxel in Stage IIIB/IV Non-small Cell Lung Cancer
Status: Enrolling
Updated: 10/29/2012
Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
Study of Orally Administered TAK-960 in Patients With Advanced Nonhematologic Malignancies
A Phase 1, Open-Label, Dose-Escalation Study of Orally Administered TAK-960, a Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Nonhematologic Malignancies
Status: Enrolling
Updated:  10/29/2012
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Study of Orally Administered TAK-960 in Patients With Advanced Nonhematologic Malignancies
A Phase 1, Open-Label, Dose-Escalation Study of Orally Administered TAK-960, a Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Nonhematologic Malignancies
Status: Enrolling
Updated: 10/29/2012
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of Orally Administered TAK-960 in Patients With Advanced Nonhematologic Malignancies
A Phase 1, Open-Label, Dose-Escalation Study of Orally Administered TAK-960, a Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Nonhematologic Malignancies
Status: Enrolling
Updated:  10/29/2012
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Study of Orally Administered TAK-960 in Patients With Advanced Nonhematologic Malignancies
A Phase 1, Open-Label, Dose-Escalation Study of Orally Administered TAK-960, a Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Nonhematologic Malignancies
Status: Enrolling
Updated: 10/29/2012
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study of GDC-0973/XL518 in Patients With Solid Tumors
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of GDC-0973/XL518 Administered Orally Daily to Subjects With Solid Tumors
Status: Enrolling
Updated:  10/29/2012
Clinical Research Facility
mi
from
Santa Clara, CA
Study of GDC-0973/XL518 in Patients With Solid Tumors
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of GDC-0973/XL518 Administered Orally Daily to Subjects With Solid Tumors
Status: Enrolling
Updated: 10/29/2012
Clinical Research Facility
mi
from
Santa Clara, CA
Click here to add this to my saved trials
Study of GDC-0973/XL518 in Patients With Solid Tumors
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of GDC-0973/XL518 Administered Orally Daily to Subjects With Solid Tumors
Status: Enrolling
Updated:  10/29/2012
Clinical Research Facility
mi
from
Ann Arbor, MI
Study of GDC-0973/XL518 in Patients With Solid Tumors
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of GDC-0973/XL518 Administered Orally Daily to Subjects With Solid Tumors
Status: Enrolling
Updated: 10/29/2012
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study of GDC-0973/XL518 in Patients With Solid Tumors
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of GDC-0973/XL518 Administered Orally Daily to Subjects With Solid Tumors
Status: Enrolling
Updated:  10/29/2012
Clinical Research Facility
mi
from
New York, NY
Study of GDC-0973/XL518 in Patients With Solid Tumors
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of GDC-0973/XL518 Administered Orally Daily to Subjects With Solid Tumors
Status: Enrolling
Updated: 10/29/2012
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Detection and/or Evaluation of Dense Breast Abnormalities Using Tomosynthesis and Digital Mammography
Assessment of Emerging Technology: Comparison of Breast Tomosynthesis and Digital Mammography in the Evaluation of Heterogeneously Dense and Extremely Dense Breasts
Status: Enrolling
Updated:  10/30/2012
University of Michigan Health System
mi
from
Ann Arbor, MI
Detection and/or Evaluation of Dense Breast Abnormalities Using Tomosynthesis and Digital Mammography
Assessment of Emerging Technology: Comparison of Breast Tomosynthesis and Digital Mammography in the Evaluation of Heterogeneously Dense and Extremely Dense Breasts
Status: Enrolling
Updated: 10/30/2012
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Role of 3D Tomography in Breast Cancer
Role of 3D Tomography in Breast Cancer
Status: Enrolling
Updated:  11/1/2012
University of Rochester Medical Center, Highland Breast Imaging Center
mi
from
Rochester, NY
Role of 3D Tomography in Breast Cancer
Role of 3D Tomography in Breast Cancer
Status: Enrolling
Updated: 11/1/2012
University of Rochester Medical Center, Highland Breast Imaging Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Capecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer
Phase I Trial of Chemoradiation With Capecitabine and Vorinostat in Pancreatic Cancer.
Status: Enrolling
Updated:  11/2/2012
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Capecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer
Phase I Trial of Chemoradiation With Capecitabine and Vorinostat in Pancreatic Cancer.
Status: Enrolling
Updated: 11/2/2012
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors
An Open-Lable Phase 1 Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  11/2/2012
Samuel Oschin Comprehensive Cancer Institute
mi
from
Los Angeles, CA
Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors
An Open-Lable Phase 1 Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 11/2/2012
Samuel Oschin Comprehensive Cancer Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Polyp Detection With The Peerscope System™
Polyp Detection With The Peerscope System™: A Randomized Tandem Colonoscopy Study
Status: Enrolling
Updated:  11/4/2012
North Shore Gasstroenterology Assoiates, P.C.
mi
from
NY, NY
Polyp Detection With The Peerscope System™
Polyp Detection With The Peerscope System™: A Randomized Tandem Colonoscopy Study
Status: Enrolling
Updated: 11/4/2012
North Shore Gasstroenterology Assoiates, P.C.
mi
from
NY, NY
Click here to add this to my saved trials
Polyp Detection With The Peerscope System™
Polyp Detection With The Peerscope System™: A Randomized Tandem Colonoscopy Study
Status: Enrolling
Updated:  11/4/2012
Southshore Gasstroenterology, P.C
mi
from
NY, NY
Polyp Detection With The Peerscope System™
Polyp Detection With The Peerscope System™: A Randomized Tandem Colonoscopy Study
Status: Enrolling
Updated: 11/4/2012
Southshore Gasstroenterology, P.C
mi
from
NY, NY
Click here to add this to my saved trials
Study of Axitinib and Temsirolimus in Solid Tumors
Phase I Study of Axitinib and Temsirolimus in Solid Tumors
Status: Enrolling
Updated:  11/5/2012
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Study of Axitinib and Temsirolimus in Solid Tumors
Phase I Study of Axitinib and Temsirolimus in Solid Tumors
Status: Enrolling
Updated: 11/5/2012
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
The Effect of Guided Imagery and Music Therapy on Post-Operative Recovery After Gynecological Oncology Surgery
The Effect of Guided Imagery and Music Therapy on Post-Operative Recovery After Gynecological Oncology Surgery
Status: Enrolling
Updated:  11/6/2012
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
The Effect of Guided Imagery and Music Therapy on Post-Operative Recovery After Gynecological Oncology Surgery
The Effect of Guided Imagery and Music Therapy on Post-Operative Recovery After Gynecological Oncology Surgery
Status: Enrolling
Updated: 11/6/2012
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Digoxin for Recurrent Prostate Cancer
A Pilot Phase II Study of Digoxin in Patients With Recurrent Prostate Cancer as Evident by a Rising PSA
Status: Enrolling
Updated:  11/6/2012
Thomas Jefferson University
mi
from
Philadelphia, PA
Digoxin for Recurrent Prostate Cancer
A Pilot Phase II Study of Digoxin in Patients With Recurrent Prostate Cancer as Evident by a Rising PSA
Status: Enrolling
Updated: 11/6/2012
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With Cisplatin
A Phase I Open-Label, Ascending Dose Cohort Study of Gemcitabine Elaidate and Cisplatin in Patients With Advanced Solid Tumors Followed by an Expanded Cohort of Patients With Stage IIIb/IV NSCLC.
Status: Enrolling
Updated:  11/7/2012
Florida Cancer Specialists
mi
from
Fort Myers, FL
A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With Cisplatin
A Phase I Open-Label, Ascending Dose Cohort Study of Gemcitabine Elaidate and Cisplatin in Patients With Advanced Solid Tumors Followed by an Expanded Cohort of Patients With Stage IIIb/IV NSCLC.
Status: Enrolling
Updated: 11/7/2012
Florida Cancer Specialists
mi
from
Fort Myers, FL
Click here to add this to my saved trials
A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With Cisplatin
A Phase I Open-Label, Ascending Dose Cohort Study of Gemcitabine Elaidate and Cisplatin in Patients With Advanced Solid Tumors Followed by an Expanded Cohort of Patients With Stage IIIb/IV NSCLC.
Status: Enrolling
Updated:  11/7/2012
Tennessee Oncology
mi
from
Nashville, TN
A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With Cisplatin
A Phase I Open-Label, Ascending Dose Cohort Study of Gemcitabine Elaidate and Cisplatin in Patients With Advanced Solid Tumors Followed by an Expanded Cohort of Patients With Stage IIIb/IV NSCLC.
Status: Enrolling
Updated: 11/7/2012
Tennessee Oncology
mi
from
Nashville, TN
Click here to add this to my saved trials
A Combination Therapy Study of MK2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010 AM5)
A Phase I Study of Oral MK2206 in Combination With Oral AZD6244 in Patients With Locally Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  11/8/2012
Clinical Research Facility
mi
from
Sacramento, CA
A Combination Therapy Study of MK2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010 AM5)
A Phase I Study of Oral MK2206 in Combination With Oral AZD6244 in Patients With Locally Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 11/8/2012
Clinical Research Facility
mi
from
Sacramento, CA
Click here to add this to my saved trials
A Combination Therapy Study of MK2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010 AM5)
A Phase I Study of Oral MK2206 in Combination With Oral AZD6244 in Patients With Locally Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  11/8/2012
Clinical Research Facility
mi
from
Philadelphia, PA
A Combination Therapy Study of MK2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010 AM5)
A Phase I Study of Oral MK2206 in Combination With Oral AZD6244 in Patients With Locally Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 11/8/2012
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Combination Therapy Study of MK2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010 AM5)
A Phase I Study of Oral MK2206 in Combination With Oral AZD6244 in Patients With Locally Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  11/8/2012
Clinical Research Facility
mi
from
San Antonio, TX
A Combination Therapy Study of MK2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010 AM5)
A Phase I Study of Oral MK2206 in Combination With Oral AZD6244 in Patients With Locally Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 11/8/2012
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  11/8/2012
GSK Investigational Site
mi
from
Glendale, AZ
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 11/8/2012
GSK Investigational Site
mi
from
Glendale, AZ
Click here to add this to my saved trials
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  11/8/2012
GSK Investigational Site
mi
from
Anaheim, CA
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 11/8/2012
GSK Investigational Site
mi
from
Anaheim, CA
Click here to add this to my saved trials
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  11/8/2012
GSK Investigational Site
mi
from
Aurora, CO
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 11/8/2012
GSK Investigational Site
mi
from
Aurora, CO
Click here to add this to my saved trials
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  11/8/2012
GSK Investigational Site
mi
from
Las Vegas, NV
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 11/8/2012
GSK Investigational Site
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  11/8/2012
GSK Investigational Site
mi
from
New York, NY
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 11/8/2012
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  11/8/2012
GSK Investigational Site
mi
from
Charleston, SC
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 11/8/2012
GSK Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  11/8/2012
GSK Investigational Site
mi
from
Knoxville, TN
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 11/8/2012
GSK Investigational Site
mi
from
Knoxville, TN
Click here to add this to my saved trials
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  11/8/2012
GSK Investigational Site
mi
from
Austin, TX
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 11/8/2012
GSK Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  11/8/2012
GSK Investigational Site
mi
from
Richmond, VA
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 11/8/2012
GSK Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  11/8/2012
GSK Investigational Site
mi
from
Kennewick, WA
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 11/8/2012
GSK Investigational Site
mi
from
Kennewick, WA
Click here to add this to my saved trials
A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors
A Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of The Anti-A5B1 Integrin Monoclonal Antibody PF-04605412 Administered Intravenously To Adult Patients With Advanced Or Metastatic Solid Tumors
Status: Enrolling
Updated:  11/9/2012
Pfizer Investigational Site
mi
from
Pittsburgh, PA
A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors
A Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of The Anti-A5B1 Integrin Monoclonal Antibody PF-04605412 Administered Intravenously To Adult Patients With Advanced Or Metastatic Solid Tumors
Status: Enrolling
Updated: 11/9/2012
Pfizer Investigational Site
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors
A Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of The Anti-A5B1 Integrin Monoclonal Antibody PF-04605412 Administered Intravenously To Adult Patients With Advanced Or Metastatic Solid Tumors
Status: Enrolling
Updated:  11/9/2012
Pfizer Investigational Site
mi
from
Bristol, TN
A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors
A Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of The Anti-A5B1 Integrin Monoclonal Antibody PF-04605412 Administered Intravenously To Adult Patients With Advanced Or Metastatic Solid Tumors
Status: Enrolling
Updated: 11/9/2012
Pfizer Investigational Site
mi
from
Bristol, TN
Click here to add this to my saved trials
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
An Open-Label, Multicenter, Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Ramucirumab (IMC-1121B) Drug Product in Combination With Eribulin Versus Eribulin Monotherapy in Unresectable, Locally-Recurrent or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated:  11/9/2012
ImClone Investigational Site
mi
from
Birmingham, AL
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
An Open-Label, Multicenter, Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Ramucirumab (IMC-1121B) Drug Product in Combination With Eribulin Versus Eribulin Monotherapy in Unresectable, Locally-Recurrent or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated: 11/9/2012
ImClone Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
An Open-Label, Multicenter, Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Ramucirumab (IMC-1121B) Drug Product in Combination With Eribulin Versus Eribulin Monotherapy in Unresectable, Locally-Recurrent or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated:  11/9/2012
ImClone Investigational Site
mi
from
Alhambra, CA
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
An Open-Label, Multicenter, Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Ramucirumab (IMC-1121B) Drug Product in Combination With Eribulin Versus Eribulin Monotherapy in Unresectable, Locally-Recurrent or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated: 11/9/2012
ImClone Investigational Site
mi
from
Alhambra, CA
Click here to add this to my saved trials
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
An Open-Label, Multicenter, Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Ramucirumab (IMC-1121B) Drug Product in Combination With Eribulin Versus Eribulin Monotherapy in Unresectable, Locally-Recurrent or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated:  11/9/2012
ImClone Investigational Site
mi
from
Aurora, CO
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
An Open-Label, Multicenter, Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Ramucirumab (IMC-1121B) Drug Product in Combination With Eribulin Versus Eribulin Monotherapy in Unresectable, Locally-Recurrent or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated: 11/9/2012
ImClone Investigational Site
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
An Open-Label, Multicenter, Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Ramucirumab (IMC-1121B) Drug Product in Combination With Eribulin Versus Eribulin Monotherapy in Unresectable, Locally-Recurrent or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated:  11/9/2012
ImClone Investigational Site
mi
from
, CT
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
An Open-Label, Multicenter, Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Ramucirumab (IMC-1121B) Drug Product in Combination With Eribulin Versus Eribulin Monotherapy in Unresectable, Locally-Recurrent or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated: 11/9/2012
ImClone Investigational Site
mi
from
, CT
Click here to add this to my saved trials
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
An Open-Label, Multicenter, Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Ramucirumab (IMC-1121B) Drug Product in Combination With Eribulin Versus Eribulin Monotherapy in Unresectable, Locally-Recurrent or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated:  11/9/2012
ImClone Investigational Site
mi
from
Fort Lauderdale, FL
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
An Open-Label, Multicenter, Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Ramucirumab (IMC-1121B) Drug Product in Combination With Eribulin Versus Eribulin Monotherapy in Unresectable, Locally-Recurrent or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated: 11/9/2012
ImClone Investigational Site
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
An Open-Label, Multicenter, Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Ramucirumab (IMC-1121B) Drug Product in Combination With Eribulin Versus Eribulin Monotherapy in Unresectable, Locally-Recurrent or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated:  11/9/2012
ImClone Investigational Site
mi
from
Atlanta, GA
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
An Open-Label, Multicenter, Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Ramucirumab (IMC-1121B) Drug Product in Combination With Eribulin Versus Eribulin Monotherapy in Unresectable, Locally-Recurrent or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated: 11/9/2012
ImClone Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
An Open-Label, Multicenter, Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Ramucirumab (IMC-1121B) Drug Product in Combination With Eribulin Versus Eribulin Monotherapy in Unresectable, Locally-Recurrent or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated:  11/9/2012
ImClone Investigational Site
mi
from
Alton, IL
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
An Open-Label, Multicenter, Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Ramucirumab (IMC-1121B) Drug Product in Combination With Eribulin Versus Eribulin Monotherapy in Unresectable, Locally-Recurrent or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated: 11/9/2012
ImClone Investigational Site
mi
from
Alton, IL
Click here to add this to my saved trials
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
An Open-Label, Multicenter, Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Ramucirumab (IMC-1121B) Drug Product in Combination With Eribulin Versus Eribulin Monotherapy in Unresectable, Locally-Recurrent or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated:  11/9/2012
ImClone Investigational Site
mi
from
Baltimore, MD
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
An Open-Label, Multicenter, Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Ramucirumab (IMC-1121B) Drug Product in Combination With Eribulin Versus Eribulin Monotherapy in Unresectable, Locally-Recurrent or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated: 11/9/2012
ImClone Investigational Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
An Open-Label, Multicenter, Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Ramucirumab (IMC-1121B) Drug Product in Combination With Eribulin Versus Eribulin Monotherapy in Unresectable, Locally-Recurrent or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated:  11/9/2012
ImClone Investigational Site
mi
from
Detroit, MI
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
An Open-Label, Multicenter, Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Ramucirumab (IMC-1121B) Drug Product in Combination With Eribulin Versus Eribulin Monotherapy in Unresectable, Locally-Recurrent or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated: 11/9/2012
ImClone Investigational Site
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
An Open-Label, Multicenter, Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Ramucirumab (IMC-1121B) Drug Product in Combination With Eribulin Versus Eribulin Monotherapy in Unresectable, Locally-Recurrent or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated:  11/9/2012
ImClone Investigational Site
mi
from
Minneapolis, MN
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
An Open-Label, Multicenter, Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Ramucirumab (IMC-1121B) Drug Product in Combination With Eribulin Versus Eribulin Monotherapy in Unresectable, Locally-Recurrent or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated: 11/9/2012
ImClone Investigational Site
mi
from
Minneapolis, MN
Click here to add this to my saved trials